Refusal By Patent Board Of Amended Claims Upheld By Federal Circuit
WASHINGTON, D.C. — A bid by a patent owner to substitute nine claims of a botulinum toxin patent following adverse post-grant review (PGR) proceedings was properly rejected by the Patent Trial...To view the full article, register now.
Already a subscriber? Click here to view full article